AbbVie - ABBV Stock Forecast, Price & News

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Wells Fargo & Company increased their price target on shares of AbbVie from $165.00 to $200.00 in a research note on Monday, May 2nd. Daiwa Capital Markets cut shares of AbbVie from an "outperform" rating to a "neutral" rating and set a $150.00 price target for the company. in a research note on Friday, May 6th. BMO Capital Markets increased their price target on shares of AbbVie from $161.00 to $174.00 and gave the company an "outperform" rating in a research note on Monday, April 25th. Atlantic Securities dropped their price target on shares of AbbVie from $178.00 to $162.00 and set a "neutral" rating for the company in a research note on Monday, August 1st. Finally, Barclays dropped their price target on shares of AbbVie to $160.00 in a research note on Tuesday, August 9th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $159.63.

AbbVie Price Performance

AbbVie stock opened at $141.29 on Friday. The firm has a market cap of $249.81 billion, a PE ratio of 20.01, a price-to-earnings-growth ratio of 4.00 and a beta of 0.70. AbbVie has a 52-week low of $105.56 and a 52-week high of $175.91. The company has a quick ratio of 0.75, a current ratio of 0.84 and a debt-to-equity ratio of 4.15. The company's 50 day moving average is $146.44 and its two-hundred day moving average is $150.50.

AbbVie (NYSE:ABBV - Get Rating) last released its earnings results on Friday, July 29th. The company reported $3.51 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.42 by $0.09. AbbVie had a net margin of 22.03% and a return on equity of 158.41%. The company had revenue of $14.58 billion for the quarter, compared to analyst estimates of $14.64 billion. During the same period in the prior year, the business earned $3.11 EPS. The firm's quarterly revenue was up 4.5% on a year-over-year basis. On average, research analysts expect that AbbVie will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 15th. Stockholders of record on Friday, July 15th were issued a $1.41 dividend. The ex-dividend date was Thursday, July 14th. This represents a $5.64 dividend on an annualized basis and a dividend yield of 3.99%. AbbVie's payout ratio is 79.89%.

Insider Activity

In other news, Vice Chairman Michael Severino sold 79,801 shares of the firm's stock in a transaction on Monday, May 23rd. The shares were sold at an average price of $150.90, for a total value of $12,041,970.90. Following the sale, the insider now directly owns 152,103 shares in the company, valued at approximately $22,952,342.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.08% of the company's stock.